The pharmacology of the cannabinoid system--a question of efficacy and selectivity.
Our knowledge of the function of the cannabinoid system in the body has been aided by the availability of pharmacological agents that affect its function. This has been achieved by the design of agents that either directly interact with the receptor (agonists and antagonist/inverse agonists) and agents that indirectly modulate the receptor output by changing the levels of the endogenous cannabinoids (endocannabinoids). In this review, examples of the most commonly used receptor agonists, antagonists/inverse agonists, and indirectly acting agents (anandamide uptake inhibitors, fatty acid amide hydrolase inhibitors, monoacylglycerol lipase inhibitors) are given, with particular focus upon their selectivity and, in the case of the directly acting compounds, efficacy. Finally, the links between the endocannabinoid and cyclooxygenase pathways are explored, in particular, with respect to agents whose primary function is to inhibit cyclooxygenase activity, but which also interact with the endocannabinoid system.
Fowler
Christopher J
CJ
Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-90187, Umeå, Sweden. cf@pharm.umu.se
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D043882:Receptors, Cannabinoid / Q000378:metabolism; D016896:Treatment Outcome
D002186:Cannabinoids; D008024:Ligands; D043882:Receptors, Cannabinoid; D011451:Prostaglandin-Endoperoxide Synthases